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Abstract
Background: The proportion of older people among the general population has risen. Staphylococcus aureus (SA)
constitutes a significant problem. Underlying disease and functional debility, predispose the older adult to
staphylococcal carriage and infection, specially bloodstream infection and pneumonia.
Methods: This is a retrospective cohort study of older patients with SA infections. We analyzed a database
containing the results of laboratory cultures from patients treated in 2013 for SA infections and selected 613
hospitalized and non-hospitalized people aged ≥60 years.
Results: The prevalence of Methicillin-resistant SA (MRSA) were significantly different in categories of patients: from
14.1% in young old, 19.5% in old old and 26.7 in longevity. MRSA was significantly more frequently reported in
cases of pneumonia, 40.4% of SA strains (p < 0.0001, OR 0.3, 95%CI 0.14–0.49). The nosocomial MRSA infections
were more common in ICU departments: prevalence 36.8%, than in non-ICU departments: prevalence 17.3% (OR 2.
8, 95%CI 1.06–7.34, p = 0.014). Bloodstream infections, which accounted for 6% of all infections, were more frequent
in males (p = 0.0231, OR 2.25, 95%CI 1.098–4.604). The greatest increase in antibiotic resistance was related to
trimethoprim/sulfamethoxazole (TMP/SXT), which increased to over 80% in the older study groups. All age groups
demonstrated increased MIC90 values for glycopeptide and tigecycline. Although strains isolated from patients in
all age groups remained sensitive to vancomycin, strains isolated from patients in the old-old and longevity groups
demonstrated resistance to teicoplanin. The MIC90 for tigecycline was the highest in the group aged >90 years.
Conclusions: MRSA constitutes a significant epidemiological problem in cases of hospital-treated pneumonia. The
findings were similar for long-term-care facilities, where MRSA appears to affect male residents in particular, although
there were fewer male residents than female residents. The low sensitivity to TMP/SXT of SA strains isolated from the
oldest patients indicates potentially serious challenges pertaining to efficacious treatment of SA infections.
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Background
The proportion of the population aged ≥65 years is rising
steadily. It is estimated that by 2025 the number of such
people will increase by more than two-fold [1]. The older
population (>65 years) is anticipated to exceed 1 billion per-
sons by 2030 [2]. The average age of European individuals
is already the highest in the world. In 2000, people aged
≥65 years represented 14% of the population, which is
expected to increase to 25% of the population by 2050 [3].
Thus, challenges associated with infections in older patients
and their impact on medical and socioeconomic systems in
developing countries require specific assessment [2, 4]. An
increased burden of infection in the older is linked to age-
related dysfunction of the immune system, malnutrition
and anatomic and physiological modifications. Antimicro-
bial therapy is often less effective in older patients owing to
the rare initiation of empiric therapy and late diagnosis
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because older individuals often exhibit fewer signs and
symptoms of infections.
Staphylococcus aureus (SA) is a microorganism that
comprises normal human flora with the capacity to cause
serious infections. SA primarily colonizes warm and moist
regions of mucous membranes, especially the nasal vesti-
bule, where it is located. Methicillin-resistant SA (MRSA) is
defined by resistance to penicillin derivatives and other anti-
microbial agents containing beta-lactam rings and remains
one of the principal multidrug-resistant bacterial pathogens
causing infections, especially nosocomial infections. MRSA
infections are associated with a worse prognosis than non-
MRSA infections [5, 6]. Methicillin resistance in SA is usu-
ally accompanied by resistance to other groups of antimicro-
bial agents, thus therapeutic options are sometimes limited
to glycopeptides or linezolid [7, 8]. In Poland, the prevalence
of MRSA is regional; in 2013, non-teaching hospitals in
southern Poland demonstrated a frequency of 15.1% [9].
However, MRSA presents a significant problem for older pa-
tients, especially those in institutional settings [10].
The aim of the study was to assess the prevalence of
MRSA in older populations in outpatient care facilities,
hospitals and long-term care facilities (LTCF) in the
provinces of Malopolska and Silesia and clarify the effect
of age on the prevalence of MRSA.
Methods
This retrospective cohort study analyzed a database contain-
ing the results of laboratory data from three cooperating
laboratories in southern Poland: The Chair of Microbiology,
Jagiellonian University Medical College in Krakow; KOR-
LAB NZOZ in Ruda Slaska; and the Microbiological
Laboratory, St. Barbara Regional Hospital in Sosnowiec be-
tween January 1, 2013 and December 31, 2013. The study
included only those records that meet the following criteria:
patients aged ≥60 years treated for SA infections between
January 1, 2013 and December 31, 2013. Patients with SA
infections were defined according to the diagnosis of the
physicians, who collected information regarding age, sex,
type of infection and place of infection treatment.
Drug resistance was determined using two methods:
manually using the Kirby-Bauer disc diffusion method
on Mueller-Hinton agar plates and automatically using
the Vitek-2® system (bioMérieux, Marcy l’Etoile, France).
Results were interpreted according to European Commit-
tee on Antimicrobial Susceptibility Testing, EUCAST
clinical breakpoints [11]. All SA strains were tested for re-
sistance to commonly used antimicrobial agents (erythro-
mycin, clindamycin, amikacin, gentamicin, tobramycin,
moxifloxacin, ciprofloxacin, tetracycline, trimethoprim/
sulfamethoxazole (TMP/SXT)). Quantitative assay for de-
termining the minimum inhibitory concentration (MIC)
of glycopeptides was performed using the vancomycin/tei-
coplanin MIC Test Strip (Liofilchem, Argenta, Poland).
MIC trends were assessed as MIC50 and MIC90 values
(MICs required to inhibit the growth of 50 and 90% of or-
ganisms, respectively) [12].
Statistical analysis
Analyses were performed using StatSoft Statistica software
(StatSoft Inc., version 10, Dell Statistica, Tulsa, OK, USA).
The odds ratio (OR) and 95% confidence interval (95%CI)
were calculated. The normality of the distribution of con-
tinuous variables was tested using the Shapiro-Wilk test.
No variables had normal distributions; thus, variables were
presented as medians and 25th (Q1) and 75th (Q3) per-
centiles. Continuous variables were tested using the
Mann-Whitney U test or Kruskal-Wallis test with appro-
priate post-hoc tests. For dichotomous variables, the Chi-
square test was used for expected frequencies >10, the
Chi-square test with Yates’ correction was used for ex-
pected frequencies between 5 and 10 and the Chi-square
test with confirmation by Fisher’s exact test was used for
expected frequencies of 5 or lower. Values of p < 0.05 were
considered statistically significant.
Results
In total, the study population included 613 participants.
Participants were categorized by age as follows: young
old: 60–74 years, N = 311; late old age (old old): 75–85
years, N = 272; and oldest age (longevity): ≥85 years, N =
30. The median age of the studied population was
72 years (Q1;Q3: 66;79 years). The median age for male
and female patients were 70 and 74 years, respectively
(p < 0.0001, OR 0.32, 95%CI 0.137–0.769) (Table 1).
Patients treated in hospitals for SA infection were usu-
ally treated in non-intensive care unit (ICU) departments
(n = 309). Bloodstream infections (BSI) accounted for 6%
of all infections and were twice as frequent in males than
in females (p = 0.0231, OR 2.25, 95%CI 1.098–4.604), des-
pite the predominance of females. Additionally, 12 cases
(67%) of BSI and pneumonia occurred in patients aged
≥75 years. Other infections (non-classified, e.g., ear or
urinary tract infections) accounted for 8% of all cases, with
more than half of the affected patients being female.
The prevalence of MRSA was significantly different in
categories of patients: from 14.1% in young old, 19.5% in
old old and 26.7 in longevity. MRSA was significantly less
frequently reported in cases of pneumonia, 40.4% of SA
strains (p < 0.0001, OR 0.3, 95%CI 0.14–0.49). The nosoco-
mial MRSA infections were more common in ICU depart-
ments: prevalence 36.8%, than in non-ICU departments:
prevalence 17.3% (OR 2.8, 95%CI 1.06–7.34, p = 0.014).
Bloodstream infections, which accounted for 6% of all in-
fections, were more frequent in males (p = 0.0231, OR 2.25,
95%CI 1.098–4.604). Additionally, MRSA tended to be as-
sociated with BSI while methicillin-susceptible SA (MSSA)
was associated with other infection types, although these
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associations were not significant (Table 2). MRSA infec-
tions were significantly less frequent among LTCF residents
(p = 0.0033, OR 0.3, 95%Cl 0.09–0.69), whereas MSSA in-
fections were significantly more frequent among patients in
non-hospital settings (p = 0.0033, OR 1.7, 95%CI 1.03–2.92)
(Table 2).
Resistance to macrolides and lincosamides was similar
among all three age groups with a slight increase in the
longevity group. Resistance to aminoglycosides and
fluoroquinolones clearly increased with age (Table 3).
The most dramatic increase in resistance was to tri-
methoprim/sulfamethoxazole (TMP/SXT); resistance in-
creased from 17% of the young old group to over 80% in
old-old and longevity groups (Table 3).
Comparison of the prevalence of the MRSA phenotype
vs. MRSA +MLSB phenotype (resistance to macrolides,
lincosamides and streptogramin B) among all three age
groups revealed that the longevity group demonstrated
significantly higher accumulated resistance compared
with the other age groups (p = 0.0371). However, no sig-
nificant difference in antibiotic resistance was observed
according to sex (Table 4).
All age groups demonstrated increased MIC90 values
for glycopeptide and tigecycline. Although strains iso-
lated from patients in all age groups remained sensitive
to vancomycin, strains isolated from patients in the old-
old and longevity groups demonstrated resistance to tei-
coplanin. The MIC90 for tigecycline was the highest in
the group aged >90 years (Table 5).
Discussion
The occurrence of MRSA in Europe displays large inter-
country variations [ECDC 2013]. A majority of the countries
reported frequencies below 20%, which has significantly de-
creased over the last 4 years [13]. The frequency of MRSA
infection is generally lower in northern Europe and higher
in southern and south-eastern Europe, however, increasing
trends were observed for four countries: Germany, Poland,
Portugal and Romania [13]. MRSA and MSSA are also fre-
quently resistant to fluoroquinolones. The report concluded
that MRSA remains a public health priority and recom-
mended comprehensive MRSA strategies targeting all
healthcare sectors (acute and ambulatory care settings and
LTCF) to curb the spread of MRSA in Europe.
It is well known that infections in older patients are a
critical medical problem [2]. Older persons generally have
greater susceptibility to infections than younger adults be-
cause aging is associated with immune dysfunction, espe-
cially in cell-mediated immunity [14]. Older patients often
require hospitalization and unfortunately contribute sub-
stantially to the influx of multidrug-resistant organisms
(MDRO) into the hospital setting [15, 16].
Table 1 The demographic characteristics of the study group
Characteristics Total (N = 613) Male
(N = 289)
Female (N = 324) OR (95%CI) P-value
Age (years)
(median, quartiles)
72 (66;79) 70,0 (65;77) 74 (66;80) N/A 0.0003
Step aging n (%) <0.0001
Young old 311 (100.0) 172 (55.3) 139 (44.7) 1.9 (1.42–2.69)
Old old 272 (100.0) 110 (40.4) 162 (59.6) 0.4 (0.27–0.52)
Longevity 30 (100.0) 7 (23.3) 23 (76.7) 0.3 (0.14–0.77)
Type of infection n (%) 0.0231
PNU 47 (100.0) 22 (46.8) 25 (53.2) 0.9 (0.54–1.79)
BSI 37 (100.0) 25 (67.6) 12 (32.4) 2.3 (1.09–4.60)
SSTI 416 (100.0) 196 (47.1) 220 (52.9) 0.9 (0.71–1.39)
EI 62 (100.0) 30 (48.4) 32 (51.6) 1.1 (0.63–1.79)
Others 51 (100.0) 16 (31.4) 35 (68.6) 0.5 (0.26–0.89)
Place of the treatment infections n (%)
INPATIENTS 430 (100.0) 213 (49.5) 217 (50.5) 1.4 (0.97–1.96) 0.0309
LTCF 16 (100.0) 3 (18.8) 13 (81.6) 0.3 (0.07–0.89)
OUTPATIENTS 167 (100.0) 73 (43.7) 94 (56.3) 0.8 (0.58–1.18)
Infections treated in hospitals (INPATIENTS N = 430, n (%))
ICU 19 (100.0) 12 (62.3) 7 (36.8) 1.8 (0.69–4.64) 0.014
non-ICU 411 (100.0) 201 (48.9) 210 (51.1)
Abbreviations: PNU pneumonia, BSI bloodstream infection, SSTI skin and soft tissue infection, EI eye infection, INPATIENTS Hospital Infection, LCTF long term care
facility, OUTPATIENTS Community Infection, ICU Intensive Care Unit, Non-ICU Non Intensive Care Unit, OR odds ratio, 95%CL 95% confidence interval, P-value
probability value, N/A not applicable/ not available?
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Additionally, MRSA presents a major problem for older
patients [10]. The emergence of bacterial resistance in
older patients may be potentially harmful in both long-
stay rehabilitation facilities and acute care settings [17].
Individuals colonized with MRSA are at increased risk of
MRSA infection and the poor functional status of older
patients is associated with MRSA carrier status [18]. The
most serious infection of the SA etiology are BSIs, particu-
larly among older male adults, patients with immunity dis-
turbances or comorbidity and also those that have
frequent health care contact [19]. Moreover, patients with
SA-BSI have an increased risk of developing associated
complications, such as acute complications (shock, adult
respiratory distress syndrome, disseminated intravascular
Table 2 Features of the etiology of infections caused by Staphylococcus aureus
Characteristics Total (N = 613) MSSA
(N = 508)
MRSA (N = 105) OR (95%CI) P-value
Age (years)
(median, quartiles)
72 (66;79) 75 (67;81) 72 (65;78) N/A 0.0048
Gender: Female 322 (100.0) 214 (82.3) 57 (17.7) 1.4 (0.93–2.16) 0.5909
Male 291 (100.0) 255 (83.5) 48 (16.5)
Step aging n (%) 0,0849
Young Old 311 (100.0) 267 (85.9) 44 (14.1) 1.5 (1.00–2.35)
Old Old 272 (100.0) 219 (80.5) 53 (19.5) 0.7 (0.49–1.13)
Longevity 30 (100.0) 22 (73.3) 8 (26.7) 0.6 (0.24–1.27)
Disease n (%) <0.0001
PNU 47 (100.0) 28 (59.6) 19 (40.4) 0.3 (0.14–0.49)
BSI 37 (100.0) 27 (73.0) 10 (27.0) 0.5 (0.25–1.14)
SSTI 416 (100.0) 350 (84.1) 66 (15.9) 1.3 (0.85–2.03)
EI 62 (100.0) 56 (90.3) 6 (9.7) 1.7 (0.72–4.06)
Others 51 (100.0) 47 (92.2) 4 (7.8) 2.6 (0.91–7.31)
Place of the treatment infections n (%) 0.0033
INPATIENTS 430 (100.0) 352 (81.4) 78 (18.1) 0.8 (0.49–1.26)
LTCF 16 (100.0) 9 (56.3) 7 (43.8) 0.3 (0.09–0.69)
OUTPATIENTS 167 (100.0) 147 (88.0) 20 (12.0) 1.7 (1.03–2.92)
Infections treated in hospitals (INPATIENTS N = 430, n (%))
ICU 19 (100.0) 12 (63.2) 7 (36.8) 2.8 (1.06–7.34) 0.014
non-ICU 411 (100.0) 340 (82.7) 71 (17.3)
Abbreviations: PNU pneumonia, BSI bloodstream infection, SSTI skin and soft tissue infection, EI eye infection, INPATIENTS Hospital infection, LCTF long term care
facility, OUTPATIENTS Community Infection, ICU Intensive Care Unit, Non-ICU Non Intensive Care Unit, OR odds ratio, 95%CL 95% confidence interval, P-value
probability value, MSSA Methicilin Sensitive Staphylococcus aureus, MRSA Methiciln Resistant Staphylococcus aureus, N/A not applicable/ not available?
Table 3 Antimicrobial resistance most often used in treating infections with Staphylococcus aureus etiology
Groups of drugs Antimicrobial % resistance in the age groups
Young Old
[N = 311]
Old-Old
[N = 272]
Longevity
[N = 30]
Macrolides Erythromycin (15 μg) 25.2 26.1 30.0
Lincosamides Clindamycin (2 μg) 22.4 22.1 30.0
Aminoglycosides Amikacin (30 μg) 25.1 23.8 41.7
Gentamicin (10 μg) 18.8 22.2 33.3
Tobramycin (10 μg) 29.4 32.7 50.0
Fluoroquinolones Moxifloxacin (5 μg) 23.7 34.5 48.1
Ciprofloxacin (5 μg) 20.8 25.2 52.9
Tetracycline Tetracycline (30 μg) 23.8 18.2 30.0
Other Trimethoprim/ Sulfamethoxazole (1.25/23.75 μg) 17.0 83.3 81.2
Linezolid (10 μg) 0 0 0
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coagulation) or infective endocarditis and metastatic sup-
portive complications [20]. Many patient factors contrib-
ute to the limited therapeutic options available including
concomitant diseases, drug-antibiotic interactions, com-
promised immunity and metabolic insufficiency.
The microbiological profile and acquisition source of
BSI have also been studied in older people, however, the
majority of these studies made no distinction between
younger and older people. Additionally, no distinction
was made within the older population itself, and identi-
fying older people at a cut-off age of 65 years, generally
corresponding to retirement age, is probably unsatisfac-
tory, especially with regard to infectious disease [21].
Notably, our results demonstrated increasing resistance
to TMP/SXT with age. Some investigators recommend
TMP/SXT for MRSA infections because of its low cost and
familiarity to health care providers as an older antimicrobial
[22]. Unfortunately, in our analysis, SA strains isolated from
older patients demonstrated significantly increased TMP/
SXT resistance, limiting its usefulness in the treatment of
patients aged ≥75 years. Lee et al. showed strains isolated
from patients with febrile urinary tract infections demon-
strating very high resistance to TMP/SXT, no metter how
old the patients were [23]. According to a study by
Leistevuo et al., TMP/SXT (or trimethoprim alone) was
most frequently prescribed antimicrobial medicine to aged
≥85 years females with urinary tract infections (37%) [17].
According to the most recent publications from the ECDC
(European Centre of Disease Control and Prevention) on
community antibiotic consumption, TMP/SXT is the low-
est consumed antimicrobial group (expressed in DDD (de-
fine daily dose) per 1000 inhabitants per day) [24] in
European countries. However, this ECDC report revealed
the highest usage of TMP/SMX in Poland (ranging from
1.0 DDD in 2008 to 1.5 DDD in 2011 per 1000 inhabitants
and per day). Finland was the second highest consumer of
TMP/SXT among European countries during this period
[24]. Unfortunately, the Finnish report did not present anti-
biotic consumption according to specific age groups. How-
ever, high antibiotic prescriptions among older patients was
confirmed in some populations [17, 25]. The key issue is
appropriateness of the antimicrobial treatment in relation
to the laboratory results, especially in general practice. The
study results of Vellinga et al. revealed that treatment of
uncomplicated UTI was considered appropriate only for
55% of the patients [26]. Moreover, it was also observed
high level of TMP/SXT resistance (30,5%) in E. coli isolated
in UTI [26].
The conducted analysis demonstrated that MRSA re-
mains a major epidemiological and therapeutic problem
not only in hospitalized patients, but also LTCF resi-
dents. Thus, infection control as practiced in hospitals
and LTCF plays a significant role in health care and pos-
sibly other institutional settings [27]. However, SA pneu-
monia is significantly more frequently managed in
hospitals in different departments, not only ICUs, and is
significantly more often associated with MRSA. The
higher MIC values observed for teicoplanin in the lon-
gevity group may also prove to be crucial, especially with
reference to patients hospitalized in non-ICU depart-
ments. According to earlier research conducted by Lee
et al. and Holland & Fowler [28], elevated MIC values
for vancomycin (>1.5 mg/L in MRSA and >1.5 mg/L in
MSSA) have been confirmed as an independent risk fac-
tor for 30-day mortality in patients with SA bacteremia.
Moreover, MIC values for teicoplanin could be consid-
ered a surrogate marker for pathogen-specific factors re-
sponsible for worse outcomes or increased virulence
secondary to antibiotic resistance [29].
The present study also demonstrated that MRSA in-
fections in LTCF residents affect males more often than
females, The results of our other study also showed
greater exposure to the MRSA infections in men than
women among diabetic patients with foot ulcers [30].
Those findings may reflect lower hygiene standards in
the elderly, especially in male gender. Inadequate hy-
giene habits can increase the risk of horizontal spread,
which is typical of MRSA strains [31].
Table 4 MRSA vs MRSA + MLSB phenotype depending on age
group and gender
Age n (%) P-value
Young old
[N = 311]
Old-old
[N = 272]
Longevity
[N = 30]
Gender Female 139 (45.1) 162 (52.6) 7 (2.3) <0.0001
Male 172 (56.4) 110 (36.1) 23 (7.5)
MRSA 44 (41.5) 53 (50.5) 8 (7.6) 0.0849
MRSA +MLSB 34 (41.5) 40 (48.8) 8 (9.8) 0.0371
Abbreviations: MRSA Methicillin-Resistant Staphylococcus aureus, MLSB Macro-
lide, Lincosamide and Streptogramin B Resistance
Table 5 MIC [mg/ml] values for drugs “last resort” of the MRSA
patients in different age categories
„Last-resort” drugs Young old Old-old Longevity
Vancomycin [N = 136]
MIC 50 0.75 0.75 0.5
MIC 90 1 1 1.5
Teicoplanin [N = 136]
MIC 50 1 1 0.75
MIC 90 2 3 3
Tigecycline [N = 230]
MIC 50 0.094 0.094 0.094
MIC 90 0.19 0.25 0.38
Abbreviations: MIC 50 minimum inhibitory concentration, that inhibits 50% of
bacterial isolates, MIC 90 minimum inhibitory concentration, that inhibits 90%
of bacterial isolates
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Study limitations
There are some limitations associated with this study. First,
the demographic information of the study population is lim-
ited. For example, previous antimicrobial usage, comorbidity,
disability and patient outcome data were not available be-
cause of the retrospective nature of the study. Additionally,
differences between age groups for hospitalization-specific
factors could not be assessed because of this data limitation.
Conclusions
Methicillin-resistant SA (MRSA) constitutes a significant
epidemiological problem in cases of hospital-treated pneu-
monia. The findings were similar for LTCF, where MRSA
appears to affect male residents in particular, although
there were fewer male residents than female residents.
The low sensitivity to TMP/SXT of SA strains isolated
from the oldest patients indicates potentially serious chal-
lenges pertaining to efficacious treatment of SA infections.
Abbreviations
95% CL: 95% Confidence interval; BSI: Bloodstream infection; ICU: Intensive
care unit; LCTF: Long term care facility; MRSA/ MSSA: Methicillin-Resistant /
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